Gag-onc fusion protein
||This article needs attention from an expert in Viruses. The specific problem is: Confusing, difficult for non-experts to understand. (June 2013)|
The gag-onc fusion protein (also written as Gag-v-Onc, with "v" indicating that the Onc sequence resides in a viral genome) is a general term for a fusion protein formed from a group-specific antigen ('gag') gene and that of an oncogene ('onc'), a gene that plays a role in the development of a cancer. Onc is a generic placeholder for a given specific oncogene, such as C-jun. (In the case of a fusion with C-jun, the resulting "gag-jun" protein is known alternatively as p65).
Gag genes are part of a general architecture for retroviruses, viruses that replicate through reverse transcription, where the gag region of the genome encodes proteins that constitute the matrix, capsid and nucleocapsid of the mature virus particles. Like in HIV's replication cycle, these proteins are needed for viral budding from the host cell's plasma membrane, where the fully formed virions leave the cell to infect other cells.
As a specific case, a Gag-v-Onc fusion protein from the Rous sarcoma virus is useful in illustrating the dual role that the fusion protein plays in both the viral and host cellular life cycle. For example, the viral gene Src (as in "sarcoma") is not necessary for viral reproduction, but does affect virulence. Due to evidence of conserved homology between the v-Src gene and its host (animal) genomes, and its non-essential status for viral reproduction, the v-Src gene is likely to have been acquired from a host genome and altered by subsequent mutations. These subsequent mutations are responsible for the oncogenic capabilities of the virus, as the normal (host) version of the Src gene, c-Src promotes survival, angiogenesis, proliferation and invasion pathways. These native pathways are disrupted in the presence of the mutant Src gene (v-Src) such that oncogenesis becomes more likely for the infected host cells, since the v-Src gene is translated into a functionally distinct version of its host counterpart.
When a viral gene is introduced into the host cell and is sufficient enough to induce oncogenesis - the creation of cancerous cells - in the infected cell line, the gene is said to be a "viral transforming gene". When this type of gene is translated to a protein, the protein is called a "transforming protein". Note that since the viral oncogenes originated from a host genome, the transformation event is different from transduction, which describes the process of introducing non-native genes to a host organism via a viral infection.
In the case of the murine leukemia viruses, a species of viruses capable of causing cancer in murines (mice), the viral life cycle can also be responsible for oncogenesis through a Gag-v-Onc fusion protein called "Mo-MuLV(src)", which is a Gag-v-Src protein capable of inducing oncogenesis in living mice.
- gag-onc Fusion Proteins at the US National Library of Medicine Medical Subject Headings (MeSH)
- Lewin, Benjamin (1999). Genes VII. USA: Oxford University Press. ISBN 978-0198792765.
- Principles of Virology, 3rd edition, Vol. 1, Molecular Biology, 2009
- Smart JE, Oppermann H, Czernilofsky AP, Purchio AF, Erikson RL, Bishop JM (October 1981). "Characterization of sites for tyrosine phosphorylation in the transforming protein of Rous sarcoma virus (pp60v-src) and its normal cellular homologue (pp60c-src)". Proc. Natl. Acad. Sci. U.S.A. 78 (10): 6013–7. doi:10.1073/pnas.78.10.6013. PMC 348967. PMID 6273838.
- Swanstrom, R.; Parker, R. C.; Varmus, H. E.; Bishop, J. M. (1983). "Transduction of a cellular oncogene: The genesis of Rous sarcoma virus". Proceedings of the National Academy of Sciences of the United States of America 80 (9): 2519–2523. doi:10.1073/pnas.80.9.2519. PMC 393857. PMID 6302692.
- . ISBN 978-1-155581-480-9 Check
|isbn=value (help). Missing or empty
- Feuerman, M. H.; Lee, W. T.; Pattengale, P. K.; Fan, H. (1988). "Comparison of three recombinant murine leukemia viruses carrying the v-src oncogene of avian sarcoma virus: Differences in in vitro transformation and in vivo pathogenicity". Molecular carcinogenesis 1 (1): 57–66. PMID 2855603.